First Publication from the NeuroDeRisk Consortium

Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and …

Press Release: NeuroDeRisk – Cracking the code of neurotoxicity

NeuroDeRisk will foster the development of innovative and safer pharmaceuticals: A new consortium of 18 international partners from academia, industry, and small and medium enterprises, aims to tackle the unmet challenge of poor prediction of neurotoxic effects in pre- clinical drug candidate assessment.